Quest Laboratories Ltd. · NSE:QUESTLAB
Quest Laboratories — H1 FY25 Earnings Presentation
31 slides from Quest Laboratories's earnings presentation, Dec 28, 2024
Slide 1: H1 FY25 Investor Presentation
aS vr Quest ~~ ey ft &_ A H1 FY25 INVESTOR PRESENTATION q
Slide 2: About Quest Laboratories Limited
About Quest Laboratories Limited Founded in June 1998, Quest Laboratories Limited specializes in manufacturing a wide range of pharmaceutical formulations, including antibiotics, antimalarials, anti-inflammatories, respiratory medications, diabetes treatments and more. Company also produces a wide r
Slide 3: Director's Take
Director’s Take “Q2/H1 has demonstrated exceptional performance, building on a solid Q1 foundation. Our growth trajectory continued to accelerate, with a remarkable 29.13% increase in EBITDA and a significant 26.74% YoY rise in PAT. This success has been driven by a well-rounded demand surge across
Slide 4: Key Facts & Figures
Key Facts & Figures 800+ Collagen 200+ H1FY25 (Cr.) Licensed Formulations Upcoming Vertical Team Size Revenue – 43.46 EBITDA – 12.20 PAT – 8.01 272+ 576+ 100% 25cr.+ Active Products Awards Winning In House Quality Order Book from Control & Laboratory Myanmar INVESTOR PRESENTATION 4
Slide 5: Vision / Mission
Vision / Mission MISSION To establish and explore To manufacture a wide global market in range of pharmaceutical pharmaceutical and key products targeting industries, delivering high- domestic, institutional and quality, affordable products exports markets for while driving innovation and sustainabl
Slide 6: Journey & Milestones
Journey & Milestones ISO / IEC 17025 : 2017 for Conversion of our Good Manufacturing General Requirements for Company from Private Practices Certificate & Good the Competence of Testing Limited to Public Laboratory Practices Services & Calibration Laboratories Limited Company 1998 2022 2024 2004 202
Slide 7: Slide 7
Slide 8: Business Overview 1/2
Business Overview 1/2 Product Verticals Pioneering upcoming Verticals Tablets ORS Powder Capsules Liquid Syrup Dry Syrup Injectables Ointment External Liquids Collagen INVESTOR PRESENTATION 8
Slide 9: Business Overview 2/2
Business Overview 2/2 Manufacturing operations depend on key raw materials, including APIs, starting Impactful Business Verticals materials, and intermediates for in-house API production. ✓ OTC Business ✓ Ethical Quest also source excipients, consumables, lab chemicals, and packaging materials ✓ Gen
Slide 10: Manufacturing Plant
Pioneering Production Excellence Tablet Compressor Tablet Coating Process Powder Mixing Process Processing Manufacturing Plant Location - • Plot No. 45, Sector III, Pithampur Industrial Area, Pithampur, Dhar - 454775, Madhya Pradesh, India. Total Area - CAP Fitting Labeling Tube Filing Process Suspe
Slide 11: Optimizing Products & Capacity
Optimizing Products & Capacity Capacity & Utilization PRODUCT FY23 FY24 Increase in % Capacity Utilized Capacity Utilized Capacity Utilized Liquid Syrup (In Lakhs Liters) 60 42 60 53.09 0.00 26.40 Tablets (In Crores) 360 242 360 278.18 0.00 14.95 Dry Syrup (In Kgs.) 90,000 17,000 90,000 29,030 0.00
Slide 12: Sectorial and Geographical Bifurcations
Sectorial and Geographical Bifurcations Revenue Bifurcation Geographical Bifurcation Sector Bifurcation for FY24 FY24 1.18% 19.08% 0.18% 0.07% 50.80% 9.22% 0.17% 36.85% 80.92% Private Public (Gov) 0.75% 0.60% Amount (In Crs.) 0.01% Private Enterprises 15.75 Public Institutions 66.81 Total 82.56 Tran
Slide 13: Key Products & Deliverables
Key Products & Deliverables INVESTOR PRESENTATION 13
Slide 14: Licenses & Certificates
Licenses & Certificates INVESTOR PRESENTATION 14
Slide 15: Distinctive Pillars of Strength
Distinctive Pillars of Strength Versatile Product Capability Dynamic Product Range Growth via Government Partnerships • Holds approvals for over 800 • Diverse portfolio of generics, branded • Participates in government tenders formulations. pharmaceuticals, OTC products, and and partners with key st
Slide 16: Industry Overview
INDUSTRY OVERVIEW
Slide 17: Pharmaceutical Industry Landscape
Pharmaceutical Industry Landscape Indian Pharmaceutical Market (In USD Global Pharmaceutical Market Billion) (In USD Billions) 450 967.12 465.15 130 65 2024 2030 2047 2024 2029 India's pharmaceutical market is projected to reach US$ The Global Pharmaceutical Manufacturing Market is 65 billion by 202
Slide 18: India Driven Growth Injectors
India driven growth Injectors Global Demand drives Domestic Pharma Growth Pharmaceutical sector is a key driver of foreign investment, ranking among India’s top 10 sectors. India's pharmaceutical exports grew 9.7% y-o-y to reach US$ 27.82 billion in FY24, India exports pharmaceuticals to over 200 co
Slide 19: Accelerators Of Pharmaceutical Expansion
Accelerators Of Pharmaceutical Expansion Increasing Investment Policy Support • India permits 100% FDI in Greenfield pharma and up to • Rs. 500 crore scheme “Strengthening of Pharmaceutical 74% in Brownfield, with higher stakes needing Industry” supports pharma clusters and MSMEs to government appro
Slide 20: Management Overview
MANAGEMENT OVERVIEW
Slide 21: Management Overview
Management Overview Mr. Anil Kumar Sabarwal Promoter , Chairman & Managing Director Holds a Secondary School Examination Certificate from Kendriya Vidyalaya Sri- ganga Nagar, Cantt Raj School, in the year 1985. He has over 25 years of experience over Quest. Mrs. Tejaswini Sabarwal Vinayak Sabarwal U
Slide 22: Way Forward
WAY FORWARD
Slide 23: Future Outlook
Future Outlook Accelerating Revenue Growth Unit Expansion & Upgradation • Revenue is projected to grow at a robust 30-35% CAGR • Plans to expand manufacturing capacity with two new for next three years. Advanced Manufacturing Plants. • Exports are expected to contribute additionally 10-15% this year
Slide 24: Financials
FINANCIALS
Slide 25: Key Financial Metrics
Key Financial Metrics Total Revenue (INR Cr.) EBITDA (INR Cr) & EBITDA Margins (%) PAT (INR Cr) & PAT Margins (%) 18 25. 00% 82.56 16 12 20. 00% 14 20. 00% 10.09 18.43% 18. 00% 61.64 19.05% 10 16. 00% 8.01 12 14. 00% 15. 00% 8 42.63 10 12.19% 13.04% 12. 00% 15.77 5.04 6 10. 00% 8 9.44% 8.14% 10. 00%
Slide 26: H1 FY25 Financial Highlights
H1 FY25 Financial Highlights Particulars (INR Crs.) H1 FY24 H1 FY25 Y-o-Y Change Revenue 41.02 42.63 Other Income 0.05 0.83 Total Income 41.07 43.46 5.82 % Raw Material Expense 25.83 23.92 Employee Benefit Expense 2.31 1.86 Other Expenses 3.49 5.49 EBITDA 9.44 12.19 29.13% EBITDA Margin (%) 22.99 28
Slide 27: Historical Income Statement
Historical Income Statement Particulars (INR Crs.) FY23 FY24 H1 FY25 Revenue 61.64 82.56 42.63 Other Income 0.23 0.23 0.83 Total Income 61.87 82.79 43.46 Raw Material Expense 41.80 52.25 23.92 Employee Benefit Expense 3.34 4.27 1.86 Other Expenses 8.66 10.50 5.49 EBITDA 8.07 15.77 12.19 EBITDA Margi
Slide 28: Historical Balance Sheet
Historical Balance Sheet Equities & Liabilities (INR Cr) FY23 FY24 H1 FY25 Assets FY23 FY24 H1 FY25 Shareholder's Fund Non Current Assets Share Capital 1.08 11.94 16.39 PP&E 9.84 10.21 11.19 Reserves & Surplus 14.02 16.70 63.42 Non Current Investment 0.08 0.08 0.32 Total Equity 15.10 28.64 79.81 Def
Slide 29: Capital Market Data
Capital Market Data Price Data (As on 13th December, 2024) INR Shareholding Pattern (As on 30th September, 2024) Share Price 110.00 34.17 Market Capitalization (Cr) 180.26 No of Share Outstanding (Cr) 16,387,200 65.83 Face Value 10.0 52 Week H/L 196.80/85.10 Promoters Public Share Performance (Up to
Slide 30: Safe Harbor
Safe Harbor This presentation, along with its accompanying slides (hereafter referred to as the “Presentation”), has been compiled by Quest Laboratories Limited (Quest, or "the Company") for informational purposes only. It does not constitute an offer, recommendation, or invitation to purchase or su
Slide 31: Quest Laboratories Limited / Confideleap Partners
Quest Laboratories Limited Confideleap Partners Corporate Office: Plot No 45 , Opp. 103-8, Lodha Eternis, MIDC, Kissan Pipe Unit 4, Pithampur Dist. Andheri East, Mumbai 400093 Dhar (M.P), 454775. Maharashtra, India. Phone: +91-9329095934 Phone: +91 85911 45959 Email: quest.tender@gmail.com Email: in